These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 6138082)

  • 1. Relationship between plasma concentration and effect of midazolam after oral and intravenous administration.
    Crevoisier C; Ziegler WH; Eckert M; Heizmann P
    Br J Clin Pharmacol; 1983; 16 Suppl 1(Suppl 1):51S-61S. PubMed ID: 6138082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relation between the clinical effect and plasma concentration of midazolam in volunteers].
    Crevoisier C; Ziegler WH; Heizmann P; Dubuis R
    Ann Fr Anesth Reanim; 1984; 3(3):162-7. PubMed ID: 6742533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites.
    Ziegler WH; Schalch E; Leishman B; Eckert M
    Br J Clin Pharmacol; 1983; 16 Suppl 1(Suppl 1):63S-69S. PubMed ID: 6138083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relation between the clinical effect and the pharmacokinetics of midazolam following i.m. and i.v. administration/2nd comm.: Pharmacokinetical aspects (author's transl)].
    Crevoisier C; Eckert M; Heizmann P; Thurneysen DJ; Ziegler WH
    Arzneimittelforschung; 1981; 31(12a):2211-5. PubMed ID: 6120700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam.
    Palkama VJ; Ahonen J; Neuvonen PJ; Olkkola KT
    Clin Pharmacol Ther; 1999 Jul; 66(1):33-9. PubMed ID: 10430107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and bioavailability of midazolam in man.
    Heizmann P; Eckert M; Ziegler WH
    Br J Clin Pharmacol; 1983; 16 Suppl 1(Suppl 1):43S-49S. PubMed ID: 6138080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam.
    Ahonen J; Olkkola KT; Neuvonen PJ
    Eur J Clin Pharmacol; 1997; 51(5):415-9. PubMed ID: 9049584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relationship between clinical effects and pharmacokinetics of midazolam on i.m. and i.v. application to volunteers/1st comm.: Clinical aspects (author's transl)].
    Ziegler WH; Thurneysen JD; Crevoisier C; Eckert M; Amrein R; Dubuis R
    Arzneimittelforschung; 1981; 31(12a):2206-10. PubMed ID: 6120699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
    Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
    Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pharmacokinetics of midazolam and loprazolam in healthy subjects after oral administration.
    Jochemsen R; van Rijn PA; Hazelzet TG; van Boxtel CJ; Breimer DD
    Biopharm Drug Dispos; 1986; 7(1):53-61. PubMed ID: 2869795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetics of midazolam in man.
    Smith MT; Eadie MJ; Brophy TO
    Eur J Clin Pharmacol; 1981 Mar; 19(4):271-8. PubMed ID: 6116606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Midazolam--does it cause resedation?
    Ruiz K; Asbury AJ; Thornton JA
    Anaesthesia; 1983 Sep; 38(9):898-902. PubMed ID: 6137969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
    Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
    Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration.
    Reed MD; Rodarte A; Blumer JL; Khoo KC; Akbari B; Pou S; Pharmd ; Kearns GL;
    J Clin Pharmacol; 2001 Dec; 41(12):1359-69. PubMed ID: 11762564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of the anxiolytic agent 8-chloro-6-(2-chlorophenyl)-4H-imidazo-[1,5-alpha] [1,4]-benzodiazepine-3-carboxamide in whole blood, plasma or urine by high-performance liquid chromatography.
    Puglisi CV; de Silva JA
    J Chromatogr; 1981 Nov; 226(1):135-46. PubMed ID: 6119318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Auditory and electroencephalographic effects of midazolam and alpha-hydroxy-midazolam in healthy subjects.
    Hotz MA; Ritz R; Linder L; Scollo-Lavizzari G; Haefeli WE
    Br J Clin Pharmacol; 2000 Jan; 49(1):72-9. PubMed ID: 10606840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships between plasma levels and psychological effects of benzodiazepines.
    Ziegler G; Ludwig L; Klotz U
    Pharmacopsychiatria; 1983 May; 16(3):71-6. PubMed ID: 6136997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of age, gender, and obesity on midazolam kinetics.
    Greenblatt DJ; Abernethy DR; Locniskar A; Harmatz JS; Limjuco RA; Shader RI
    Anesthesiology; 1984 Jul; 61(1):27-35. PubMed ID: 6742481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
    Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
    Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal midazolam plasma concentration profile and its effect on anxiety associated with dental procedures.
    Burstein AH; Modica R; Hatton M; Gengo FM
    Anesth Prog; 1996; 43(2):52-7. PubMed ID: 10323126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.